Osaka, Japan

Miki Hirai




Average Co-Inventor Count = 4.4

ph-index = 1

Forward Citations = 10(Granted Patents)


Company Filing History:


Years Active: 2013-2018

Loading Chart...
Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Miki Hirai: Innovator in Pharmaceutical Compounds

Introduction: Miki Hirai is a notable inventor based in Osaka, Japan, recognized for her contributions to the field of pharmaceutical compounds. With a total of four patents to her name, Miki has made significant strides in developing innovative drugs that benefit human health.

Latest Patents: Miki Hirai's latest patents include groundbreaking inventions such as a nitrogen-containing saturated heterocyclic compound, which is designed to serve as a renin inhibitor. This compound is characterized by a complex formula where R represents a cycloalkyl group, and various other groups and functional components work together to provide therapeutic benefits. These advancements highlight her expertise in creating compounds with potential pharmacological applications.

Career Highlights: Throughout her career, Miki has been associated with prominent pharmaceutical companies, including Mitsubishi Tanabe Pharma Corporation and Shanghai Pharmaceuticals Holding Co., Ltd. Her work in these companies has allowed her to develop a deep understanding of pharmaceutical innovations, furthering her contributions to the industry.

Collaborations: Miki Hirai has collaborated with esteemed colleagues such as Toru Iijima and Hiroshi Sugama. Their joint efforts have fostered a creative environment conducive to the development of cutting-edge pharmaceutical solutions, combining their expertise to enhance the quality and effectiveness of their inventions.

Conclusion: Miki Hirai stands out as an influential figure in the field of pharmaceuticals, showcasing her prowess as an inventor through her innovative patents. Her contributions are not only vital in advancing medical science but also in enhancing the healthcare industry, making her a remarkable asset in the research and development of new therapeutic agents.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…